Secukinumab

Increasing the dosage of secukinumab failed to improve ankylosing spondylitis outcomes among patients who initially demonstrated an inadequate treatment response, according to data published in Rheumatology.

Secukinumab was shown to be safe and efficacious in treating psoriasis in patients with skin of color, according to a study.

Nearly all rheumatologists who responded to a recent survey reported patients with giant cell arteritis are in dire need of new treatments, according to a market analysis from Spherix Global Insights.

Although TNF inhibitors remain the first choice biologic for many rheumatologists treating psoriatic arthritis, interleukin-17 inhibitors may soon overtake them, according to a market analysis from Spherix Global Insights.

Secukinumab did not reach proof of concept in patients with lichen planus, according to results of a phase 2 study.

Patients with plaque psoriasis that have lower baseline blood monocyte counts may respond to secukinumab therapy earlier than patients with higher counts, according to a study.

Novartis sales grew 12% on a constant currency basis, with core operating income up 21%, in the third quarter of 2023 compared with this time last year, according to a company press release.

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to data presented at ACR Convergence 2023.

The FDA has approved Cosentyx for the treatment of adults with moderate to severe hidradenitis suppurativa, Novartis announced in a press release.